Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Evaluation of anti-tumor necrosis factor levels and anti-tumor necrosis factor antibodies in rheumatic diseases treated with infliximab and adalimumab; preliminary results from a local registry.

Rosas, J.
Llinares-Tello, Francisca
Senabre, J. M.
Santos-Soler, G.
Santos-Ramírez, C.
Salas, E.
Barber, X.

November 2014

Resumen del trabajo presentado al "Annual Scientific Meeting of the American College of Rheumatology...

OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service

Chanchlani, Neil
Bewshea, Claire M.
Kennedy, Nicholas A.
Ahmad, Tariq
McDonald, Timothy J.
Nice, Rachel
Goodhand, James R.
Perry, Mandy

January 2020

Background Anti-drug antibodies can affect biopharmaceutical pharmacokinetics by increasing or decr...

Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay

van Aalen, Eva A.
de Vries, Ivar R.
Hanckmann, Eva T.L.
Stevens, Jeannot R.F.
Romagnoli, Thomas R.
Derijks, Luc J.J.
Broeren, Maarten A.C.
Merkx, Maarten

November 2023

Therapeutic drug monitoring (TDM) of tumor necrosis factor-α (TNFα)-inhibitors adalimumab and inflix...

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Llinares-Tello, Francisca
Gomez de Salazar, José Rosas
Senabre Gallego, José Miguel
Santos Soler, Gregorio
Santos Ramírez, Carlos
Salas Heredia, Esteban
Molina García, Juan

October 2012

Llinares-Tello, F.; Gomez De Salazar, JR.; Senabre Gallego, JM.; Santos Soler, G.; Santos Ramírez, C...

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Anne Emmanuelle Berger
Aude Gleizes
Louis Waeckel
Xavier Roblin
Roman Krzysiek
Salima Hacein-Bey-Abina
Alessandra Soriano
Stephane Paul

August 2022

Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decis...

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Gehin, Johanna Elin
Goll, Guro Løvik
Brun, Marthe Kirkesæther
Jani, Meghna
Bolstad, Nils
Syversen, Silje Watterdal

January 2022

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substa...

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays

Bian, Sumin
Van Stappen, Thomas
Baert, Filip
Compernolle, Griet
Brouwers, Els
Tops, Sophie
Vries, Annick de
Rispens, Theo
Lammertyn, Jeroen
Vermeire, Séverine
Gils, Ann

June 2016

A number of assays are currently available to support therapeutic drug monitoring of adalimumab. A c...

The New Test for Monitoring Infliximab Therapy: From Laboratory to Clinical Practice

De Santis, Elena
Melegari, Alessandra
Bonaguri, Chiara
Sandri, Gilda
Mascia, Maria Teresa
Gaiani, Federica
Pecoraro, Valentina
De Angelis, Gianluigi
Trenti, Tommaso

January 2018

Biological agents for anti-tumor necrosis factor-α therapy have revolutionized treatments for autoim...

The new test for monitoring infliximab therapy: From laboratory to clinical practice

De Santis, Elena
Melegari, Alessandra
Bonaguri, Chiara
Sandri, Gilda
Mascia, Maria Teresa
Gaiani, Federica
Pecoraro, Valentina
De Angelis, Gianluigi
Trenti, Tommaso

January 2018

Background: Biological agents for anti-tumor necrosis factor-Î± therapy have revolutionized treatmen...

Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab

Bian, Sumin
Ferrante, Marc
Gils, Ann

March 2017

With respect to patient safety and long-term efficacy, immunogenicity of therapeutic antibodies rema...

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Svenson, M.
Geborek, P.
Saxne, Tore
Bendtzen, K.

January 2007

Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibod...

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

Meroni, Pier Luigi
Cattaneo, Antonino
Valesini, Guido
VALENTINI, GABRIELE
AYALA, FABIO

January 2015

Aim: To assess the putative link between antibody formation to adalimumab, infliximab and etanercept...

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.

Meroni PL
Ayala F
Cattaneo A
Valesini G.
VALENTINI, Gabriele

January 2015

AIM: To assess the putative link between antibody formation to adalimumab, infliximab and etanercep...

Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods

Tron, Camille
Lemaitre, Florian
Bros, Pauline
Goulvestre, Claire
Franck, Benedicte
Mouton, Nicolas
Bagnos, Sandrine
Coriat, Romain
Khoudour, Nihel
Lebert, Dorothee
Blanchet, Benoit

June 2022

International audienceBackground: This study compared the performance of plasma infliximab and adali...

Therapeutic drug monitoring of tumour necrosis factor alpha inhibitors in inflammatory joint diseases

Gehin, Johanna Elin

January 2022

Antibody-based biopharmaceuticals have revolutionised treatment of inflammatory joint diseases in th...

Evaluation of anti-tumor necrosis factor levels and anti-tumor necrosis factor antibodies in rheumatic diseases treated with infliximab and adalimumab; preliminary results from a local registry.

Rosas, J.
Llinares-Tello, Francisca
Senabre, J. M.
Santos-Soler, G.
Santos-Ramírez, C.
Salas, E.
Barber, X.

November 2014

Resumen del trabajo presentado al "Annual Scientific Meeting of the American College of Rheumatology...

OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service

Chanchlani, Neil
Bewshea, Claire M.
Kennedy, Nicholas A.
Ahmad, Tariq
McDonald, Timothy J.
Nice, Rachel
Goodhand, James R.
Perry, Mandy

January 2020

Background Anti-drug antibodies can affect biopharmaceutical pharmacokinetics by increasing or decr...

Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay

van Aalen, Eva A.
de Vries, Ivar R.
Hanckmann, Eva T.L.
Stevens, Jeannot R.F.
Romagnoli, Thomas R.
Derijks, Luc J.J.
Broeren, Maarten A.C.
Merkx, Maarten

November 2023

Therapeutic drug monitoring (TDM) of tumor necrosis factor-α (TNFα)-inhibitors adalimumab and inflix...

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Llinares-Tello, Francisca
Gomez de Salazar, José Rosas
Senabre Gallego, José Miguel
Santos Soler, Gregorio
Santos Ramírez, Carlos
Salas Heredia, Esteban
Molina García, Juan

October 2012

Llinares-Tello, F.; Gomez De Salazar, JR.; Senabre Gallego, JM.; Santos Soler, G.; Santos Ramírez, C...

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Anne Emmanuelle Berger
Aude Gleizes
Louis Waeckel
Xavier Roblin
Roman Krzysiek
Salima Hacein-Bey-Abina
Alessandra Soriano
Stephane Paul

August 2022

Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decis...

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Gehin, Johanna Elin
Goll, Guro Løvik
Brun, Marthe Kirkesæther
Jani, Meghna
Bolstad, Nils
Syversen, Silje Watterdal

January 2022

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substa...

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays

Bian, Sumin
Van Stappen, Thomas
Baert, Filip
Compernolle, Griet
Brouwers, Els
Tops, Sophie
Vries, Annick de
Rispens, Theo
Lammertyn, Jeroen
Vermeire, Séverine
Gils, Ann

June 2016

A number of assays are currently available to support therapeutic drug monitoring of adalimumab. A c...

The New Test for Monitoring Infliximab Therapy: From Laboratory to Clinical Practice

De Santis, Elena
Melegari, Alessandra
Bonaguri, Chiara
Sandri, Gilda
Mascia, Maria Teresa
Gaiani, Federica
Pecoraro, Valentina
De Angelis, Gianluigi
Trenti, Tommaso

January 2018

Biological agents for anti-tumor necrosis factor-α therapy have revolutionized treatments for autoim...

The new test for monitoring infliximab therapy: From laboratory to clinical practice

De Santis, Elena
Melegari, Alessandra
Bonaguri, Chiara
Sandri, Gilda
Mascia, Maria Teresa
Gaiani, Federica
Pecoraro, Valentina
De Angelis, Gianluigi
Trenti, Tommaso

January 2018

Background: Biological agents for anti-tumor necrosis factor-Î± therapy have revolutionized treatmen...

Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab

Bian, Sumin
Ferrante, Marc
Gils, Ann

March 2017

With respect to patient safety and long-term efficacy, immunogenicity of therapeutic antibodies rema...

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Svenson, M.
Geborek, P.
Saxne, Tore
Bendtzen, K.

January 2007

Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibod...

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis

Meroni, Pier Luigi
Cattaneo, Antonino
Valesini, Guido
VALENTINI, GABRIELE
AYALA, FABIO

January 2015

Aim: To assess the putative link between antibody formation to adalimumab, infliximab and etanercept...

New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.

Meroni PL
Ayala F
Cattaneo A
Valesini G.
VALENTINI, Gabriele

January 2015

AIM: To assess the putative link between antibody formation to adalimumab, infliximab and etanercep...

Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods

Tron, Camille
Lemaitre, Florian
Bros, Pauline
Goulvestre, Claire
Franck, Benedicte
Mouton, Nicolas
Bagnos, Sandrine
Coriat, Romain
Khoudour, Nihel
Lebert, Dorothee
Blanchet, Benoit

June 2022

International audienceBackground: This study compared the performance of plasma infliximab and adali...

Therapeutic drug monitoring of tumour necrosis factor alpha inhibitors in inflammatory joint diseases

Gehin, Johanna Elin

January 2022

Antibody-based biopharmaceuticals have revolutionised treatment of inflammatory joint diseases in th...

Evaluation of anti-tumor necrosis factor levels and anti-tumor necrosis factor antibodies in rheumatic diseases treated with infliximab and adalimumab; preliminary results from a local registry.

Rosas, J.
Llinares-Tello, Francisca
Senabre, J. M.
Santos-Soler, G.
Santos-Ramírez, C.
Salas, E.
Barber, X.

November 2014

Resumen del trabajo presentado al "Annual Scientific Meeting of the American College of Rheumatology...

OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service

Chanchlani, Neil
Bewshea, Claire M.
Kennedy, Nicholas A.
Ahmad, Tariq
McDonald, Timothy J.
Nice, Rachel
Goodhand, James R.
Perry, Mandy

January 2020

Background Anti-drug antibodies can affect biopharmaceutical pharmacokinetics by increasing or decr...

Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay

van Aalen, Eva A.
de Vries, Ivar R.
Hanckmann, Eva T.L.
Stevens, Jeannot R.F.
Romagnoli, Thomas R.
Derijks, Luc J.J.
Broeren, Maarten A.C.
Merkx, Maarten

November 2023

Therapeutic drug monitoring (TDM) of tumor necrosis factor-α (TNFα)-inhibitors adalimumab and inflix...

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Abstract

Extracted data

Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab

Abstract

Extracted data

Related items

Related items